Bluejay Diagnostics (BJDX) Non-Current Deferred Tax Liability (2020 - 2021)
Bluejay Diagnostics recorded quarterly Non-Current Deferred Tax Liability of $26860.0 in Q4 2021, down 63.32% quarter-over-quarter from $73232.0 in Q4 2020, and down 63.32% year-over-year from $73232.0 in Q4 2020.
Bluejay Diagnostics' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $26860.0 for Q4 2021.
- In Q4 2021, Non-Current Deferred Tax Liability fell 63.32% year-over-year to $26860.0; the TTM figure through Dec 2021 stood at $26860.0 (down 63.32% YoY), while the FY2021 annual figure was $26860.0, down 63.32% from the prior year.
- Non-Current Deferred Tax Liability came in at $26860.0 for Q4 2021 at Bluejay Diagnostics, down from $73232.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $73232.0 in Q4 2020 to a low of $26860.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Bluejay Diagnostics | 572,394.44 | -3.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 26,860.00 |
| Dec 31, 2021 | 26,860.00 |
| Dec 31, 2020 | 73,232.00 |
| Dec 31, 2020 | 73,232.00 |